Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R



TSX:CXR.R - Post by User

Post by Roller007on Jul 30, 2016 6:50am
209 Views
Post# 25097970

It's about Viberzi.

It's about Viberzi. Allergen the maker of Viberzi, the newest IBS treatment, is pushing the FDA to discontinue donnatel Understandably so since its introduction early this year.   There are no issues whatsoever with donnatel efficacy or safety.  At close to $3000 Viberzi is at five times the price of donnatel and with harsher side effects.  There are solid evidence that the FDA has been reviewing the status of donnatel but this is a lengthy process.  
<< Previous
Bullboard Posts
Next >>